177 related articles for article (PubMed ID: 38099497)
21. ZNF397 Loss Triggers TET2-driven Epigenetic Rewiring, Lineage Plasticity, and AR-targeted Therapy Resistance in AR-dependent Cancers.
Xu Y; Wang Z; Sjöström M; Deng S; Wang C; Johnson NA; Gonzalez J; Li X; Metang LA; Tirado CR; Mukherji A; Wainwright G; Yu X; Yang Y; Barnes S; Hofstad M; Zhu H; Hanker A; He HH; Chen Y; Wang Z; Raj G; Arteaga C; Feng F; Wang Y; Wang T; Mu P
bioRxiv; 2023 Oct; ():. PubMed ID: 37961351
[TBL] [Abstract][Full Text] [Related]
22. Targeting Key Players of Neuroendocrine Differentiation in Prostate Cancer.
Zamora I; Freeman MR; Encío IJ; Rotinen M
Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37761978
[TBL] [Abstract][Full Text] [Related]
23. FOXA1 inhibits prostate cancer neuroendocrine differentiation.
Kim J; Jin H; Zhao JC; Yang YA; Li Y; Yang X; Dong X; Yu J
Oncogene; 2017 Jul; 36(28):4072-4080. PubMed ID: 28319070
[TBL] [Abstract][Full Text] [Related]
24. Epigenetic reprogramming during prostate cancer progression: A perspective from development.
Goel S; Bhatia V; Biswas T; Ateeq B
Semin Cancer Biol; 2022 Aug; 83():136-151. PubMed ID: 33545340
[TBL] [Abstract][Full Text] [Related]
25. RNA Splicing of the BHC80 Gene Contributes to Neuroendocrine Prostate Cancer Progression.
Li Y; Xie N; Chen R; Lee AR; Lovnicki J; Morrison EA; Fazli L; Zhang Q; Musselman CA; Wang Y; Huang J; Gleave ME; Collins C; Dong X
Eur Urol; 2019 Aug; 76(2):157-166. PubMed ID: 30910347
[TBL] [Abstract][Full Text] [Related]
26. Current advances of targeting epigenetic modifications in neuroendocrine prostate cancer.
Cheng WC; Wang HJ
Tzu Chi Med J; 2021; 33(3):224-232. PubMed ID: 34386358
[TBL] [Abstract][Full Text] [Related]
27. The Role of Lineage Plasticity in Prostate Cancer Therapy Resistance.
Beltran H; Hruszkewycz A; Scher HI; Hildesheim J; Isaacs J; Yu EY; Kelly K; Lin D; Dicker A; Arnold J; Hecht T; Wicha M; Sears R; Rowley D; White R; Gulley JL; Lee J; Diaz Meco M; Small EJ; Shen M; Knudsen K; Goodrich DW; Lotan T; Zoubeidi A; Sawyers CL; Rudin CM; Loda M; Thompson T; Rubin MA; Tawab-Amiri A; Dahut W; Nelson PS
Clin Cancer Res; 2019 Dec; 25(23):6916-6924. PubMed ID: 31363002
[TBL] [Abstract][Full Text] [Related]
28. Extracellular signal-regulated kinase mediates chromatin rewiring and lineage transformation in lung cancer.
Inoue Y; Nikolic A; Farnsworth D; Shi R; Johnson FD; Liu A; Ladanyi M; Somwar R; Gallo M; Lockwood WW
Elife; 2021 Jun; 10():. PubMed ID: 34121659
[TBL] [Abstract][Full Text] [Related]
29. A transgenic mouse model of metastatic prostate cancer originating from neuroendocrine cells.
Garabedian EM; Humphrey PA; Gordon JI
Proc Natl Acad Sci U S A; 1998 Dec; 95(26):15382-7. PubMed ID: 9860977
[TBL] [Abstract][Full Text] [Related]
30. The ELAVL3/MYCN positive feedback loop provides a therapeutic target for neuroendocrine prostate cancer.
Ji Y; Zhang W; Shen K; Su R; Liu X; Ma Z; Liu B; Hu C; Xue Y; Xin Z; Yang Y; Li A; Jiang Z; Jing N; Zhu HH; Dong L; Zhu Y; Dong B; Pan J; Wang Q; Xue W
Nat Commun; 2023 Nov; 14(1):7794. PubMed ID: 38016952
[TBL] [Abstract][Full Text] [Related]
31. GRK3 is a direct target of CREB activation and regulates neuroendocrine differentiation of prostate cancer cells.
Sang M; Hulsurkar M; Zhang X; Song H; Zheng D; Zhang Y; Li M; Xu J; Zhang S; Ittmann M; Li W
Oncotarget; 2016 Jul; 7(29):45171-45185. PubMed ID: 27191986
[TBL] [Abstract][Full Text] [Related]
32. Activated ALK Cooperates with N-Myc via Wnt/β-Catenin Signaling to Induce Neuroendocrine Prostate Cancer.
Unno K; Chalmers ZR; Pamarthy S; Vatapalli R; Rodriguez Y; Lysy B; Mok H; Sagar V; Han H; Yoo YA; Ku SY; Beltran H; Zhao Y; Abdulkadir SA
Cancer Res; 2021 Apr; 81(8):2157-2170. PubMed ID: 33637566
[TBL] [Abstract][Full Text] [Related]
33. N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer.
Dardenne E; Beltran H; Benelli M; Gayvert K; Berger A; Puca L; Cyrta J; Sboner A; Noorzad Z; MacDonald T; Cheung C; Yuen KS; Gao D; Chen Y; Eilers M; Mosquera JM; Robinson BD; Elemento O; Rubin MA; Demichelis F; Rickman DS
Cancer Cell; 2016 Oct; 30(4):563-577. PubMed ID: 27728805
[TBL] [Abstract][Full Text] [Related]
34. The β
Braadland PR; Ramberg H; Grytli HH; Urbanucci A; Nielsen HK; Guldvik IJ; Engedal A; Ketola K; Wang W; Svindland A; Mills IG; Bjartell A; Taskén KA
Mol Cancer Res; 2019 Nov; 17(11):2154-2168. PubMed ID: 31395667
[TBL] [Abstract][Full Text] [Related]
35. Roles of achaete-scute homologue 1 in DKK1 and E-cadherin repression and neuroendocrine differentiation in lung cancer.
Osada H; Tomida S; Yatabe Y; Tatematsu Y; Takeuchi T; Murakami H; Kondo Y; Sekido Y; Takahashi T
Cancer Res; 2008 Mar; 68(6):1647-55. PubMed ID: 18339843
[TBL] [Abstract][Full Text] [Related]
36. Potential therapeutic effect of epigenetic therapy on treatment-induced neuroendocrine prostate cancer.
Xu X; Huang YH; Li YJ; Cohen A; Li Z; Squires J; Zhang W; Chen XF; Zhang M; Huang JT
Asian J Androl; 2017; 19(6):686-693. PubMed ID: 27905327
[TBL] [Abstract][Full Text] [Related]
37. A novel mechanism of SRRM4 in promoting neuroendocrine prostate cancer development via a pluripotency gene network.
Lee AR; Gan Y; Tang Y; Dong X
EBioMedicine; 2018 Sep; 35():167-177. PubMed ID: 30100395
[TBL] [Abstract][Full Text] [Related]
38. The long noncoding RNA H19 regulates tumor plasticity in neuroendocrine prostate cancer.
Singh N; Ramnarine VR; Song JH; Pandey R; Padi SKR; Nouri M; Olive V; Kobelev M; Okumura K; McCarthy D; Hanna MM; Mukherjee P; Sun B; Lee BR; Parker JB; Chakravarti D; Warfel NA; Zhou M; Bearss JJ; Gibb EA; Alshalalfa M; Karnes RJ; Small EJ; Aggarwal R; Feng F; Wang Y; Buttyan R; Zoubeidi A; Rubin M; Gleave M; Slack FJ; Davicioni E; Beltran H; Collins C; Kraft AS
Nat Commun; 2021 Dec; 12(1):7349. PubMed ID: 34934057
[TBL] [Abstract][Full Text] [Related]
39. c-MYC drives histone demethylase PHF8 during neuroendocrine differentiation and in castration-resistant prostate cancer.
Maina PK; Shao P; Liu Q; Fazli L; Tyler S; Nasir M; Dong X; Qi HH
Oncotarget; 2016 Nov; 7(46):75585-75602. PubMed ID: 27689328
[TBL] [Abstract][Full Text] [Related]
40. Wntless expression promotes lineage plasticity and is associated with neuroendocrine prostate cancer.
D'Abronzo LS; Lombard AP; Ning S; Armstong CM; Leslie AR; Sharifi M; Schaaf ZA; Lou W; Gao AC
Am J Clin Exp Urol; 2022; 10(5):299-310. PubMed ID: 36313205
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
